• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Rituximab in Primary Membranous Nephropathy With Severe CKD.

作者信息

Naik Sachin, Shukla Shubham, Kumar Vinod, Sain Thakur, Sekar Aravind, Pal Deeksha, Kumar Ashwini, Minz Ranjana, Rathi Manish, Nada Ritambhra, Kohli Harbir Singh, Ramachandran Raja

机构信息

Department of Nephrology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.

Department of Dermatology, Venereology and Leprosy, Postgraduate Institute of Medical Education and Research, Chandigarh, India.

出版信息

Kidney Int Rep. 2023 Apr 1;8(6):1270-1271. doi: 10.1016/j.ekir.2023.03.020. eCollection 2023 Jun.

DOI:10.1016/j.ekir.2023.03.020
PMID:37284669
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10239766/
Abstract
摘要

相似文献

1
Rituximab in Primary Membranous Nephropathy With Severe CKD.利妥昔单抗治疗合并严重慢性肾脏病的原发性膜性肾病
Kidney Int Rep. 2023 Apr 1;8(6):1270-1271. doi: 10.1016/j.ekir.2023.03.020. eCollection 2023 Jun.
2
Monthly mini-dose rituximab for primary anti-PLA2R-positive membranous nephropathy: a personalized approach.每月小剂量利妥昔单抗治疗原发性抗 PLA2R 阳性膜性肾病：一种个体化方法。
BMC Nephrol. 2023 May 26;24(1):146. doi: 10.1186/s12882-023-03206-1.
3
Rituximab In The Treatment Of Refractory Idiopathic Membranous Nephropathy In Pakistani Population.利妥昔单抗治疗巴基斯坦人群难治性特发性膜性肾病
J Ayub Med Coll Abbottabad. 2019 Apr-Jun;31(2):265-268.
4
Rituximab in Patients With Phospholipase A2 Receptor-Associated Membranous Nephropathy and Severe CKD.利妥昔单抗用于磷脂酶A2受体相关膜性肾病和重度慢性肾脏病患者
Kidney Int Rep. 2019 Dec 20;5(3):331-338. doi: 10.1016/j.ekir.2019.12.006. eCollection 2020 Mar.
5
Evaluation of efficacy of rituximab for membranous nephropathy: A systematic review and meta-analysis of 11 studies.评价利妥昔单抗治疗膜性肾病的疗效：11 项研究的系统评价和荟萃分析。
Nephrol Ther. 2022 Apr;18(2):104-112. doi: 10.1016/j.nephro.2021.10.002. Epub 2022 Jan 21.
6
The Efficacy of Rituximab in the Treatment of Membranous Nephropathy.利妥昔单抗治疗膜性肾病的疗效。
J Nepal Health Res Counc. 2021 Jan 21;18(4):580-587. doi: 10.33314/jnhrc.v18i4.2481.
7
Treatment of idiopathic membranous nephropathy in adults: KDIGO 2012, cyclophosphamide and cyclosporine A are out, rituximab is the new normal.成人特发性膜性肾病的治疗：KDIGO 2012指南指出，环磷酰胺和环孢素A已不再适用，利妥昔单抗成为新的常用药物。
Clin Kidney J. 2019 Sep 30;12(5):629-638. doi: 10.1093/ckj/sfz127. eCollection 2019 Oct.
8
High-Dose Rituximab and Early Remission in PLA2R1-Related Membranous Nephropathy.高剂量利妥昔单抗治疗 PLA2R1 相关膜性肾病的早期缓解作用。
Clin J Am Soc Nephrol. 2019 Aug 7;14(8):1173-1182. doi: 10.2215/CJN.11791018. Epub 2019 Jul 24.
9
The STARMEN trial indicates that alternating treatment with corticosteroids and cyclophosphamide is superior to sequential treatment with tacrolimus and rituximab in primary membranous nephropathy.STARMEN 试验表明，在原发性膜性肾病中，与他克莫司和利妥昔单抗序贯治疗相比，皮质类固醇和环磷酰胺交替治疗更具优势。
Kidney Int. 2021 Apr;99(4):986-998. doi: 10.1016/j.kint.2020.10.014. Epub 2020 Nov 7.
10
Rituximab or Cyclophosphamide in the Treatment of Membranous Nephropathy: The RI-CYCLO Randomized Trial.利妥昔单抗或环磷酰胺治疗膜性肾病：RI-CYCLO随机试验
J Am Soc Nephrol. 2021 Apr;32(4):972-982. doi: 10.1681/ASN.2020071091. Epub 2021 Mar 1.

本文引用的文献

1
Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases.KDIGO 2021肾小球疾病管理指南执行摘要。
Kidney Int. 2021 Oct;100(4):753-779. doi: 10.1016/j.kint.2021.05.015.
2
Rituximab in Patients With Phospholipase A2 Receptor-Associated Membranous Nephropathy and Severe CKD.利妥昔单抗用于磷脂酶A2受体相关膜性肾病和重度慢性肾脏病患者
Kidney Int Rep. 2019 Dec 20;5(3):331-338. doi: 10.1016/j.ekir.2019.12.006. eCollection 2020 Mar.
3
Rituximab for non-responsive idiopathic membranous nephropathy in a Chinese cohort.利妥昔单抗治疗中国特发性膜性肾病无应答患者。
Nephrol Dial Transplant. 2018 Sep 1;33(9):1558-1563. doi: 10.1093/ndt/gfx295.